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Chronic heart failure (CHF) represents a very common condition that is currently one 
of the leading causes of the morbidity and mortality in industralized countries. A deeper 
understanding of the pathophysiology of CHF and the associated compensatory mechanisms 
has allowed the implementation of newer treatment regimens including ACE inhibitors, beta-
blockers and spironolactone. These drugs are able to slow progression and improve prognosis 
of the disease. However, inspite of substantial improvements in pharmacological treatment 
that have been made over last decades, 5 to 15% of the CHF population continues to suffer 
from persistent severe symptoms. The rest of CHF population could be divided in two groups 
of similar size: one with mild and one with moderately severe symptoms1. Unfortunately, only 
some patients with advanced CHF are appropriate candidates for the heart transplant              
as an ultimate treatment modality in CHF. 
The finding that cardiac pacing is able to improve the hemodynamic status in some 
patients with advanced CHF has ushered a new era in management of this condition – era      
of so called cardiac resynchronization therapy (CRT). The widespread use of CRT was 
predominantly based on the recognition that the dyssynchronous activation of the heart, 
especially of the ventricles, can be a factor associated with further progression of CHF and 
worse prognosis2.  Furthermore, CRT was documented to slow or even stop this process, 
induce reverse remodeling3-5 and reduce mortality6,7. 
However, despite growing knowledge about the mechanism of how CRT works, there 
are still unanswered questions, especially regarding 1) the usefulness of various pacing 
strategies in the treatment of the CHF and 2) the identification of different factors that can 
modify the magnitude of improvement during CRT or predict non-responderity to this 
therapy. Therefore, the aim of this dissertation was to focus on these issues.  
1. DEFINITION AND EPIDEMIOLOGY OF CHRONIC HEART FAILURE
CHF is pathophysiologically defined as the affliction of the heart that is associated 
with reduced cardiac output despite sufficient ventricular filling. As a result, the heart is not 
able to meet the metabolic demands of the tissues (delivery of the oxygen, CO2 and              
the metabolic byproducts). Heart failure without the decrease of cardiac output may occur 
during excessive increase of the ventricular filling pressure8. 
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In the routine clinical practice, the diagnosis and the treatment have focused on CHF 
as a clinical syndrome that is characterized by ventricular dysfunction and one or more signs 
of back- and/or forward failure (dyspnea, fatique, edemas). A precise estimate                        
of the incidence and prevalence of CHF is difficult to obtain because it depends                     
on the definition of CHF and early recognition of the disease. Using the above definition, 
CHF affects 1 to 5% of the population or 10 to 50 million people in Western countries8,9,10. 
The prevalence rapidly increases with age >65years9-11. Despite all advances                           
in pharmacotherapy, the amount of people suffering from CHF is increasing every year      
with an annual incidence about 2-3‰ 10,12. The reasons for the growing incidence                
and prevalence of CHF are mainly related to ageing of the population and to the advances 
made in hypertensive and coronary heart disease therapy that leads to longer life-expectancy 
in these patients13. 
Although new pharmacological interventions improved the survival of CHF, it still 
remains a condition with a high mortality rate13. Some studies indicate that the annual 
mortality of stable CHF reaches 10-20% and that only 30-45% of the CHF population is still 
alive 5 years after initial diagnosis of CHF13,14. The mortality rate is approximately six           
or seven times greater in a CHF population as compared to the general population of the same 
age15. The mortality of patients with a new-onset HF is even higher than in those with stable 
CHF and reaches 30% in the first 6months after the diagnosis16,17.
The predominant causes of death 
in CHF population are progressive heart 
failure and sudden death. A conservative 
estimate is that about 50% of CHF 
patients die due to further progression of 
CHF and about 50% die suddenly18. 
Interestingly, it seems that mode of death 
is dependent on the severity of CHF. 
While patients in functional class NYHA II die predominantly on a sudden, unexpected death, 
further progression of CHF is the leading cause of death in patients in functional class NYHA 
IV19 (Figure 1). The knowledge about what causes the progression of the CHF is limited.       
It may be a result of recurrent and undersensed or unrecognized myocardial ischemia, 
arrhythmias, remodeling of the left ventricle (LV) or its combination20. Also sudden death 
does not represent a homogenous entity. As ICDs reduce the risk of sudden death by about 
50%, it seems that almost 50% of sudden deaths may not be primarily arrhythmic21. 
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2. IMPORTANT ELECTROMECHANICAL FEATURES OF CHRONIC 
HEART FAILURE WITH REGARD TO CARDIAC RESYNCHRONIZATION 
THERAPY - PATHOPHYSIOLOGICAL NOTES
A complex pathophysiologic process altering both electrical and mechanical events 
during the cardiac cycle is often present in patients with advanced CHF. The changes result 
from a modified microstructure of the myocardium and from the fully expressed 
compensatory mechanisms22,23. They may affect both the working myocardium, thus leading 
to the deterioration of ventricular function and size, and/or specialized myocytes                     
of the conduction system, thus harming one or more of its functions. It is: 1/ a sufficient heart 
rate reflecting actual metabolic demand, 2/ an optimal timing of the atrial contraction         
with regard to the ventricular systole, and 3/ a synchronous activation and contraction            
of the ventricles.
CHF is often associated with an alteration of some of these functions. It can result       
in sinus node dysfunction manifesting as the chronotropic incompetence. In combination     
with the pharmacological adrenergic blocade, it can cause worsening of the exercise tolerance       
in CHF patients24. 
The prolonged atrioventricular (AV) conduction shifts the atrial contraction             
with regard to the ventricular systole, thus producing AV dyssynchrony. In such case,           
the atrial contraction may fuse with the early passive filling phase and limit atrial contribution 
to the ventricular filling. In addition, AV conduction >250ms is associated with a shortening 
of the diastolic philling phase. Moreover, optimal timing of atrial systole is important           
for a proper function of mitral valve. Prolonged AV conduction may cause its insufficient 
closing and presystolic mitral regurgitation25,26. 
However, among all above mentioned variables, the changed activation sequence        
of the ventricles seems to be the most crucial for the hemodynamic performance of the failing 
heart. Different ventricular conduction abnormalities, reflected in the widening and changed 
morphology of the QRS complex on the surface ECG, may occur in CHF as will be discussed 
later. They change electrical and mechanical interactions between the right and left ventricle 
(interventricular dyssynchrony) and/or between the opposite walls of the LV during              
the cardiac cycle (intraventricular dyssynchrony). 
On an individual basis, total ventricular asynchrony may result from either 
interventricular or intraventricular dyssynchrony or from combination of them. In addition, 
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AV asynchrony may participate on the hemodynamic worsening and progression of CHF       
in some patients. It was estimated that ventricular dyssynchrony is present in approximately 
20-30% of patients with CHF27. More importantly, there is a growing evidence that               
the presence of LV dyssynchrony (mainly on the intraventricular level) is related                    
to the prognosis in CHF patients28,29. 
In addition, there is a close relationship        
and interdependence of ventricular dysfunction, 
dilatation of the ventricle(s) and conduction 
disturbances (on both the atrioventricular (AV)      
and ventricular level)30-32. Both the degree of left-
ventricular (LV) dysfunction and the duration            
of QRS complex were identified as the independent 
predictors of death in CHF population33-36. Moreover, 
higher mortality was found in patients with LV 
systolic dysfunction, depending on the severity          
of conduction disturbances as reflected in QRS duration27,37 (Figure 2).
2.1. ELECTRICAL ACTIVATION OF THE VENTRICLES PHYSIOLOGICALLY 
AND DURING LBBB
In the normal hearts, electrical activation of both ventricles is preceded                       
by depolarization of the His-Purkinje system. It results in a rapid and almost simultaneous 
activation of both ventricles spreading from few separate regions reflecting the bundle 
branching. The rest of the heart is than activated quickly with total ventricular activation time 
80-100ms38-40. The activation wavefront of the RV started at the free wall and spreads to the 
interventricular septum (IVS) with the latest RV activation located usually posterobasally or 
anterobasally39. Independently to the QRS axis, the latest LV activation is located mostly in 
the basal posterolateral region38,39. 
Although different ventricular conduction delays can be found in patients with CHF, 
conduction disturbances with left bundle branch block (LBBB) morphology predominate. 
Prevalence of LBBB is about 30% in CHF population >65years, while it reaches only 1-3%   
in the general population of the same age33,34. In addition, the presence of LBBB, but neither 
right bundle-branch block nor nonspecific intraventricular conduction delay, seems to be 
associated with a higher morbidity and mortality in asymptomatic and apparently healthy 
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patients41 and their risk increases in the presence of concomitant heart disease and/or 
CHF34,35.
The presence of typical LBBB significantly modifies the ventricular activation 
sequence. RV usually precedes LV activation42,43. Although prolonged in some cases, RV 
activation pattern is usually similar to that observed during normal sinus beat39. On the 
contrary, LV exhibits mostly different activation sequence with right-to-left transseptal 
conduction39,42-44. The patterns of LV activation are variable, but the posterolateral basal LV 
region frequently represents an area with the latest activation39,40,42,45,46. Due to the changed 
activation pattern and significant reduction of the conduction velocities39, the total LV 
activation time is prolonged in most patients with LBBB39,40,42,44,45. 
Prolonged and changed ventricular activation pattern (as reflected in the morphology, 
axis and duration of the QRS complex) may result from either prolonging between RV and 
LV activation onset (interventricular delay), between activation of opposing walls of the LV 
(intraventricular delay) or from combination of them47,48. In this context, QRS duration can 
serve as a marker of total ventricular electrical asynchrony. However, it similarly reflects LV 
intraventricular and interventricular dyssynchrony29. 
Despite similar QRS duration and morphology fullfilling WHO criteria of LBBB 
(Table 1), the activation sequence may vary significantly based on both underlying heart 
disease and case to case. Some studies indicate differences in ventricular activation pattern 
between coronary artery disease (CAD) and idiopathic dilated cardiomyopathy (DCM) with 
more frequent intraventricular 
dyssynchrony in CAD and 
predominant interventricular 
dyssynchrony in DCM40,42.          
In accordance with that, CAD 
patients exhibit rather nonspecified 
conduction delay or LBBB-like 
pattern on the surface ECG, 
whereas true complete LBBB 
tends to be present more often in 
DCM40. 
The interindividual variability of ventricular activation sequence is expressed 
especially in patients with CAD, depending on the extent and location of the postinfarction 
scar. Conduction velocity varies between regions and is mostly reduced close to the scar site. 
11
In contrast to CAD, patients with DCM more often exhibit homogenous right to left activation 
with globally reduced conduction velocity39,40. These heterogeneities in the character and 
duration of ventricular activation may be explained by different histopathology in DCM         
as compared to CAD as the conduction delay strongly depends on architecture of interstitial 
fibrosis and on the direction of wavefront propagation with respect to the fiber direction49. 
2.2. MECHANICAL VENTRICULAR ACTIVATION UNDER PHYSIOLOGIC 
CONDITIONS AND DURING LBBB
Normally, mechanical activation starts with fiber shortening in the isovolumic 
contraction phase and onset of both systolic and diastolic events of the LV slightly preceeds 
or coincides with that of RV47,50-52.  Mechanical activation usually starts near the 
interventricular septum, concordantly with the electrical one. The opposing walls of the LV 
and free wall of the RV are mechanically activated in a homogenous way with the base 
activated last. Simultaneous inward motion of IVS and LV lateral wall and similar extent and 
time course of contraction between various LV regions ensure effective pump function of the 
heart52,53. 
There is a solid evidence that LBBB itself leads to dyssynchrony and could promote 
LV remodelling in already dysfunctional ventricle. LBBB prolongs and/or delays mechanical 
activation of the ventricles, especially of the LV, on inter- and/or intraventricular level51,53,54. 
The dearrangement of the ventricular contraction sequence is associated with a deterioration 
of LV systolic and diastolic function as reflected by a decrease in the maximal rate of rise of 
LV pressure (dP/dt max) and aortic pulse pressure, by an increase of LV end-diastolic 
pressure, worsening of the LV relaxation etc.47,50,51,53. 
From prognostic point of view, the presence of LV intraventricular electromechanical 
dyssynchrony, QRS duration >140ms and LV ejection fraction <25% were identified            
as the independent predictors of CHF decompensation during long-term28. On the contrary, 
presence of the interventricular dyssynchrony does not seem to be associated with a worse 
prognosis29. 
INTERVENTRICULAR DYSSYNCHRONY
The presence of LBBB reverses physiological sequence of cardiac cycle events: the 
RV systole and diastole onset markedly precedes onset of systole and diastole of the LV, thus 
causing interventricular dyssynchrony (Figure 3). Premature RV electrical and mechanical 
activation leads to an early increase in RV pressure as compared to LV pressure, thus 
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reversing the transseptal pressure gradient during RV isovolumic phase and displacing IVS 
into the cavity of LV47,50,51,55. The opposite movement of the IVS is seen in the late systole.
Besides increased preejection time of the LV due to the delayed initiation of LV 
activation, LV systole is often also 
prolonged in the presence of 
LBBB. In addition, delayed aortic 
closure and mitral valve opening 
cause prolongation of the 
isovolumic relaxation time, thus 
causing shortening of the LV 
filling time relatively to RV and limiting the stroke volume51,56. 
Abnormal or paradoxical septal motion present in patients with CHF and LBBB is, 
therefore, a result of either reversal of transseptal pressure gradient (RV contracts during end-
diastolic phase of the LV) or relative increase in RV volume (RV filling time is relatively 
longer than the LV filling time). The abnormal septal movement reduces global LV ejection 
fraction in LBBB patients51. The greater the interventricular dyssynchrony, the greater the 
depression of LVEF and the greater related LV dilatation could be expected53,57. Interestingly, 
correlation between QRS duration and interventricular asynchrony was demonstrated in some 
studies47,58.
INTRAVENTRICULAR DYSSYNCHRONY
In the presence of LBBB, various contraction patterns over the LV can be found as      
a result of delayed activation. Typically, the inward motion of the IVS induced by both its 
earlier activation and reversed transseptal gradient is present in the early systole. Later on, 
IVS moves away from the posterior wall of the LV at the time when the more delayed LV 
walls start to contract. The opposite is true for the LV free wall. The pre-stretch of this region, 
caused by the absence of activation in the early systole, is followed by the contraction that 
appears as the IVS begin to relax50,59,60. Hemodynamically, the opposite movement of the IVS 
and LV posterolateral wall during the systole is associated with a decrease in septal 
contribution to stroke volume50,51. In this context, the presence of significant delay between 
contraction of the IVS and the lateral wall of the LV >60ms was shown to be a prerequisite 
for the LV ejection fraction improvement during CRT61. All the above mentioned changes 
may also cause or deteriorate functional mitral regurgitation62,63.
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It seems that the regional differences in the contraction sequence are related to local 
variability of the myofibre length during asynchronous activation (as produced by either 
LBBB or RV apical pacing)59. In the early-activated sites, rapid and intensive shortening       
of the myocardium is present as an afterload of this region is still very low. This leads            
to a significant prestretching of the opposite walls that are not activated at that time yet. As        
a result of the LV pressure increase, regions with late activation present with longer myofibres 
at the time when all LV walls are already activated. Based on the local “Frank-Starling” 
relation, the later activated regions contract more vigorously and exhibit enhanced shortening 
during the ejection period59,60,64. Contraction of these segments may cause rebound stretch   
and a second phase of shortening in the early-activated sites during their relaxation period. 
Transient ventricular contraction patterns can be seen in other LV regions depending             
on the distance from the early and late activated site59,65. Interestingly, regional differences    
in the contraction sequence during asynchronous activation may be less pronounced during 
higher LV filling pressure66.  
It seems that these variations of the contraction pattern may also explain                    
the inhomogeneous distribution of perfusion and metabolic demand in the presence                
of asynchronous LV contraction67-69. Mechanical work of the early-activated regions could be 
reduced up to 50% during asynchronous activation59. Regional work is a good predictor         
of regional myocardial oxygen consumption69. Thus, reduced glucose uptake and perfusion   
of the IVS in the presence of asynchronous actvation may be explained by abnormal 
contraction pattern with the decreased mechanical work in this region70. The opposite is true 
for the LV free wall where the enhanced regional work is accompanied by an increased blood 
flow and metabolic demand. In addition, the extent of wall motion abnormalities and            
the perfusion defects induced by asynchronous activation increase with time and are 
associated with gradual LV pump function deterioration67. Moreover, asymmetric 
hypertrophy of the LV with microstructural desarrangement develops over long-term period 
in the presence of LBBB or during RV apical pacing71,72. Interestingly, the most pronounced 
hypertrophy is present usually in the late activated regions (higher workload)72. 
The above process, called cardiac remodeling, is characterized by changed genome 
expression and modifications on the molecular, cellular, and interstitial level that occur after 
cardiac injury. It finally results in an altered shape, size and function of the heart. In addition, 
other factors such as hemodynamic load or neurohormonal activation may contribute              
to progression of cardiac remodeling73. The surrogate measures for ventricular remodeling 
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such as LV ejection fraction (LVEF), LV end-diastolic and end-systolic volumes and/or 
diameters are often used. 
2.3. COUPLING OF ELECTRICAL AND MECHANICAL EVENTS 
Insight into the physiology and pathophysiology of electrical and mechanical 
activation suggests that there are differences in coupling of electrical and mechanical events 
throughout the myocardium. In the normal heart, a gradient of electromechanical interval   
was demonstrated between endo- and epicardium with relatively faster coupling                     
in the epicardium74. 
Some studies indicate that this electromechanical delay becomes even more 
pronounced during asynchronous activation52,75, being dependent on both: 1) the type             
of conduction delay75 and 2) the pacing site52. Along these lines, electromechanical delay       
is greater during LBBB as compared with right bundle-branch block and during single-site 
right ventricular (RV) pacing as compared with single-site LV pacing. In addition, it seems 
that the later regional activation of the LV occurs in the presence of asynchronous activation, 
the greater the time interval between regional electrical activation and the onset of local fibre 
shortening. These observations suggest that mechanical asynchrony may be larger than         
the electrical dyssynchrony, at least in some patients with conduction disturbances. 
3. CARDIAC RESYNCHRONIZATION THERAPY (CRT)
3.1. INTRODUCTION
In medicine, the term “cardiac pacing” indicates iatrogenic manipulation of the cardiac 
rhythm. In contrast to conventional cardiac pacing that corrects bradyarrhythmias, CRT is not 
primarily indicated for rhythm correction but rather for a restoration of synchronous 
ventricular activation, i.e. for correction of all types of dyssynchrony.  
The strategy of pacing for the treatment of CHF is not new. Dual-chamber pacing   
was already used in the 80´s to improve hemodynamics in selected CHF patients76,77.          
The pilot studies using short AV delay and ventricular lead placed in the RV apex          
(DDD-RVA) demonstrated significant clinical improvement (decreased NYHA class, 
reduction of pulmonary edema, heart size and the degree of mitral regurgitation).                 
The underlying mechanism of this beneficial effect of DDD-RVA pacing seemed to be         
the augmentation of stroke volume due to LV diastolic filling time prolongation and reduction 
of mitral regurgitation. Both these effects were primarily caused by appropriate shortening      
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of the AV delay78,79. However, significant hemodynamic improvement during DDD-RVA 
pacing was not reproduced in the subsequent trials80,81. 
The detail analysis of different studies implies that DDD-RVA pacing with short      
AV delay may lead to hemodynamic and clinical improvement only in a carefully selected 
population of symptomatic CHF patients with rather long spontaneous AV conduction, 
prolonged functional mitral regurgitation (450ms) and significant shortening of the LV 
filling-time (200ms at rest)82. Positive impact of the AV delay optimization in others is very 
probably counterbalanced by deleterious effect of a single-site RVA pacing that itself causes 
significant ventricular asynchrony and hemodynamic deterioration similar to that during 
LBBB83-85. 
The important turn in the treatment of CHF by ventricular pacing occurred when       
the so called biventricular pacing (BVP) was introduced, i.e. pacing from more sites in both 
ventricles. Although the effect of simultaneous pacing from two ventricular sites                     
in the structurally intact heart was studied in the experimental model years ago55, the first 
human study describing positive acute effect of BVP after cardiac surgery was published      
as late as in 199586. Later on, the impact of varying ventricular pacing sites started to be 
evaluate also among patients with advanced CHF87-89. It was clearly shown that stimulation   
of LV, either solely or in combination with simultaneous RV pacing, is superior to stimulation 
of RV alone in terms of the hemodynamic performance. Interestingly, some other studies 
indicated superiority of one pacing mode only (BVP or single-site LV pacing (LVP))            
in approximately 80% of the CHF patients90. On the other hand, improvement during BVP    
or LVP does not occur in all patients with advanced CHF as these pacing modes are only 
effective in patients with manifest dyssynchrony91. In the absence of ventricular 
dyssynchrony, not only the LV pump function does not improve, but may even 
deteriorate65,92,93. 
Proposed mechanism underlying response to different pacing strategies in patients 
with CHF and ventricular dyssynchrony seems to be the restoration of more coordinated 
activation and contraction sequence of the heart. The fact that the response is present also      
in patients with chronic atrial fibrillation with slow or no conduction through the AV node 
(i.e. in the absence of atrial contribution to the ventricular filling) confirms that                     
the hemodynamic improvement during LVP or BVP is not achieved only through restoration 
of AV synchrony94-97. 
All pacing strategies that are able to reduce antioventricular and ventricular 
dyssynchrony and thus enhance hemodynamic in CHF have been grouped under a unifying 
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term of CRT. In this context, it has been estimated that approximately 10% of patients        
with CHF might be candidates for this therapy98.
3.2. INTRA- AND INTERVENTRICULAR MECHANICAL RESYNCHRONIZATION 
DURING CRT
It was shown earlier that the maximal improvement of the LV function is present when 
the intraventricular dyssynchrony is corrected, relatively independent of the degree                
of interventricular dyssynchrony. Thus, for successful CRT, pacing strategy and/or LV pacing 
site that provide maximum of intraventricular resynchronization should be selected44,91,93. 
Resynchronization of ventricular contraction can be achieved when two activation wavefronts 
from the opposing walls merge together somewhere in the middle of the LV during the late 
systole. It results in a ventricular contraction pattern that is similar to that observed during 
normal sinus beat, including equivalent orientation of the mean vector of ventricular 
contraction65. Despite that, however, the total duration of the mechanical activation during 
CRT was shown to be longer as compared with normal sinus rhythm65. 
During BVP, resynchronization is ensured by pacing of the LV free wall and RV.       
In LVP, on the contrary, it is produced by a merge of pacing-induced wavefront originating   
at the LV free wall with spontaneous activation via the right bundle44,90,91,99. An underlying 
mechanism responsible for intraventricular resynchronization in both BVP and LVP is less 
early and late stretch and rebound contractions of the opposing walls as compared               
with baseline asynchronous activation59,65,99. 
However, hemodynamic improvement by LVP in patients with CHF could also          
be demonstrated in the setting of very short AV delay or in the presence of atrial fibrillation 
with limited AV conduction94. Therefore, it is conceivable that other mechanisms may 
contribute to the benefit of LVP. In this context, some investigators suggest that the so-called 
diastolic ventricular interaction may play a role during LVP100. The theory presumes that      
in the presence of high central venous pressure, RV occupies much of the pericardial space 
and limits filling of the LV. In such situation, LV preexcitation enables the LV to fill before 
the RV and due to elevated LV preload increases the Frank-Starling effect. On the other hand, 
it can not be excluded that the elevated LV preload during LVP, in contrast to BVP,                
is responsible for lower degree of LV reverse remodeling that was observed during long-term 
LVP101.
Other studies also indicate significant differences between BVP and LVP with regard 
to modification of ventricular dyssynchrony102,103: 
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It seems that the intraventricular resynchronization in BVP is complex. On one side, 
BVP prolongs the electromechanical delay (as measured by the mechanical response          
with respect to the QRS onset) in the regions close to IVS. LV free wall contraction remains 
the same or is advanced to less extent. As a result, different regions of the LV contract 
approximately simultaneously and synchronously during BVP3,102. Because of concomitant 
prolongation of electromechanical coupling even in RV with respect to LV, BVP reduces also 
interventricular dyssynchrony3,102,104. 
Timing of the increase in LV 
pressure then coincides with that     
of RV and normal transseptal 
pressure gradient is restored.            
In addition and in contrast to LVP, 
BVP shortens the systolic phase due 
to the reduction of LV preejection 
time, thus prolonging the diastolic 
filling time3,97 (Figure 4). 
On the other hand, LVP decreases intraventricular dyssynchrony by simultaneous 
delaying of all segments of the LV102. As a result, contraction is more homogeneous, but         
it occurs later with regard to the electrical activation. This can lead to prolongation                 
of the isovolumic contraction phase, shortening of the LV diastolic filling and worsening       
of the interventricular dyssynchrony as compared to BVP102,103. On the other site, ejection 
time is similar in both BVP and LVP97.
3.3. IMPACT OF CRT ON THE HEMODYNAMIC PERFORMANCE
Various studies have demonstrated significant improvement of parameters reflecting 
LV systolic function such as LV dP/dt max, pulse pressure, cardiac output and ejection 
fraction during CRT50,87,89,101,105,106. Some other studies have shown that the greater              
the baseline mechanical asynchrony, the more pronounced resynchronization and LVEF 
increase during CRT could be expected57,91. Furthermore, the extent of acute systolic 
improvement is proportional to the decrease in biventricular asynchrony57. Importantly, this 
positive change in systolic function during CRT occurs without change of the filling pressure 
(in fact, the filling pressure can even decrease). Therefore, restoration of more coordinated 
ventricular contraction sequence during CRT reflects rather improved contractility87.              
In addition, resynchronized ventricular contraction and more coordinated function                  
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of the papillary muscles are also often responsible for reduction of mitral regurgitation that,    
in turn, may further improve hemodynamic status107. Acute hemodynamic improvement 
occurs immediately after the onset of pacing and is frequently sensed by the patient                
as the sudden clinical improvement.  
More interestingly, CRT has also impact on cardiac oxygen consumption108.               
In contrast to positive inotropic agents (such as dobutamine) that increase myocardial oxygen 
consumption for a given rise of contractility, BVP is able to induce comparable increase         
in contractility without increased energetic demand108. Some studies have also shown          
that hemodynamic improvement during CRT is associated with restoration of more 
homogenous glucose metabolism and perfusion in the ventricles109. In addition, CRT seems   
to modify the neurohormonal activity as it is associated with reduced sympathetic nervous 
activity and lowering of the plasma brain natriuretic peptid (BNP) level110,111.
3.4. CLINICAL IMPROVEMENT
Studies of acute hemodynamic changes may not necessarily predict long-term effect   
of CRT. In this respect, clinical efficacy of CRT has been studied in multiple randomized 
and/or non-randomized clinical trials. An overview of the most important clinical trials           
is given in a review article “Is right ventricular outflow tract pacing an alternative to left 
ventricular/ biventricular pacing?” that is part of this dissertation. Briefly, besides 
enhancement of the LV systolic function and reverse remodeling of the LV (discussed later), 
BVP is able to improve quality of life, NYHA class and exercise tolerance in patients         
with advanced CHF. 
Metaanalysis of large clinical CRT trials revealed 8-point improvement                      
on the Minnesota Living with Heart Failure Questionnaire that represents standardized 
questionaire for the assessment of the quality of life among patients with CHF112. This 
improvement was shown to be greater than that defined in the placebo-controlled trials113     
and also greater than the improvement of quality of life demontrated in recent heart failure 
trials targeted on CHF pharmacotherapy114. 
Regaring NYHA class, around 60% of BVP recipients were shown to improve by      
at least 1 NYHA class as compared with 37% of controls112. On the other hand, higher 
prevalence of the improvement in NYHA class than the echocardiographically detected 
reverse remodeling indicates possible participation of placebo effect among                    
NYHA responders. 
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CRT is also associated with an improved exercise tolerance. Metaanalysis has shown 
improvement in 6-minute walk test distance with a mean difference 30m in patients            
with NYHA class III and IV before CRT. In addition, BVP is associated with an increase in 
peak oxygen consumption of about 0,7ml/kg/min as assessed by cardiopulmonary stress 
testing112. 
Long-term effect of LVP was assessed in some studies and compared with that 
observed during BVP. Results of these studies imply that LVP is associated with comparable 
long-term improvement of NYHA class, QOL and exercise tolerance as BVP115-118. Such 
encouraging results led finally to approval of the concept of CRT for hemodynamic support  
in patients with advance CHF by the U.S.Food and Drug Administration in 2001.
3.5. CRT AND REVERSE REMODELING OF THE HEART
Reduced wall stress, enhanced LV pump function and increased efficiency at a lower 
preload levels during long-term BVP are associated with reverse remodeling, i.e. with            
a decrease in the end-diastolic and the end-systolic volumes3,99,119,120. The time-dependent 
improvement of LV function and size during CRT were demonstrated in both, non-controlled 
studies3,101 as well as in multicentric clinical trials7,120-122. From the clinical point of view, 
reverse remodeling appears to be one of the most important achievments as it can be 
considered an ultimate goal of any treatment for CHF. 
Importantly, the interruption of BVP is associated with a new deterioration                  
of the cardiac function during the off-pacing period3. As the hemodynamic worsening does 
not occur immediately after CRT termination, non-decreasing LV ejection fraction               
and cardiac output found during transient stop of CRT is likely to reflect real persistent effect 
or functional reverse remodeling. However, long-term BiV is associated also with reduction 
of LV end-diastolic and end-systolic volumes and diameters that reflect rather structural 
reverse remodeling3. 
Observations of some studies imply that the degree of LV end-diastolic volume 
reduction and LVEF increase during CRT depends on the size and function before pacing 
onset as CRT nonresponders tend to have more elevated baseline LV end-diastolic volume 
and lower LVEF121. 
The impact of LVP on the reverse remodeling seems to be different from that during 
BVP. It was shown that LVP is associated with a significant increase in LVEF. However, 
LVP does not seem to produce such changes in LV volumes as BVP, at least not 
constantly101. The reason for these differences between both pacing strategies are not fully 
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understood yet, but it may be caused by a different mechanical activation                              
and electromechanical coupling, especially in the early systole, that cause prolongation          
of isovolumic contraction phase, shortening of the LV filling time and higher LV preload       
as compared with BiV. 
3.6. IMPACT OF CRT ON HOSPITALIZATION FOR HEART FAILURE AND 
MORTALITY
Nowadays, there is a strong evidence that CRT, in addition to above mentioned acute 
and long-term effects, reduces the rate of hospitalizations for heart failure and that this 
therapy is also associated with a decreased mortality. 
Until recently, only data from meta-analyses of large clinical trials on CRT aspired to 
address this issue112,123. They suggested that BiV is able to reduce both all-cause mortality and 
hospitalizations for heart failure in appropriately selected population of patients with 
symptomatic CHF, low LVEF and prolonged QRS duration. Those meta-analyses shown that 
CRT is associated with a 25% relative reduction in all cause mortality, caused mainly by the 
40% reduction in deaths due to progression of CHF, and a 29-35% reduction of 
hospitalizations for heart failure. Conclusions of these meta-analyses were recently supported 
by the results of the mortality trials COMPANION6 and CARE-HF7. The first trial has shown 
a significant reduction of the combined end-point of all-cause mortality and all-cause 
hospitalization by approximately 20%. The CRT-associated reduction of mortality in 
COMPANION6 was similar to that reported in the mentioned metaanalysis123, 24% and 23%, 
respectively. In addition, it was reported comparable reduction of the hospitalization for heart 
failure (34% reduction in death plus heart failure hospitalizations in COMPANION trial and 
29% reduction in heart failure hospitalization in the metaanalysis6,123, respectively). 
The later study, CARE-HF7, assessed the impact of CRT on the risk of cardiovascular 
complications and death as compared with standard medical treatment and demonstrated clear 
reduction by 37% of both during CRT. The all-cause mortality was reduced by 36% and heart 
failure hospitalization by 52% in the CRT arm as compared to optimal medical therapy alone. 
Using hazard ratios, it was calculated that one death and three hospitalizations for severe 
cardiovascular events are prevented for every nine CRT device.
This effect of CRT is comparable with that found in beta-blockers124, ACE 
inhibitors125 and aldosterone antagonists126. Importantly, the efect of CRT on mortality 
becomes apparent by 3months after the implantation as it reflects rather impact of LV reverse 
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remodeling than the acute neurohormonal changes112. Better survival during CRT was shown 
to be predominantly due to the reduction in deaths for terminal progression of CHF112. 
The results of COMPANION trial6 indicate, in addition, further reduction of mortality 
when combining CRT with implantable cardioverter-defibrillator (ICD) as a tool for 
preventing sudden cardiac death. It was shown that CRT pacemakers reduced combined end-
point of all-cause mortality and all-cause hospitalization by 20%, whereas CRT defibrillators 
by 36%. 
Such results suggest that the positive impact of CRT on morbidity and mortality may 
be caused by an improvement of cardiac performance and that combination of CRT with ICD 
may additionally reduce the risk of sudden cardiac death.
3.7. CRT NONRESPONDERS
Currently accepted criteria for selection of suitable CRT recipients (practical 
guidelines of ACC/AHA, ESC and Czech Society of Cardiology127-129) are based on the results 
of large multicenter studies and consist from:
- CHF with persistent moderate to severe symptoms (NYHA III-IV) despite optimized 
pharmacotherapy
- LV dysfunction (LVEF ≤ 35%)
- Presence of ventricular dyssynchrony (until now defined by QRS duration  120ms, 
usefulness of different echocardiographic parameters of mechanical dyssynchrony      
is still assessed)
In addition, concomitant dilatation of LV is ussualy present (LV end-diastolic diameter 
(LVEDD) ≥ 55mm) in CRT recipients.
In appropriate candidates, combined device (CRT+ ICD) is indicated.
However, despite extensive research in this field, some limitations and unresolved 
issues in CRT still exist. The crucial one is the identification of nonresponders to CRT           
as approximately 30% of CRT recipients do not respond to this therapy appropriately130-132. 
On the other hand and surprisingly, there is still not a uniform definition of CRT                 
non-responder. In fact, different studies used different definition: 
In acute hemodynamic studies, the response to CRT was qualified by the increase       
of pulse pressure ≥5%133 or change of dP/dt134. However, as the goal of this therapy is mainly 
to improve the long-term outcome, most of the clinical studies have evaluated changes          
of some other variables. The nonresponder rate is generally lower (11-25%) in the studies 
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using subjective capacity (NYHA class ≥1135,136, quality of life136) or exercise tolerance (peak 
VO2max ≥10%135, 6-minute walk test improvement ≥10%137) as a definition of response. 
Using “harder” end-points such as LV reverse remodeling (LV end-systolic volume reduction 
≥15%, relative increase of LVEF ≥25%107,121,138,139) or “hard” end-points (hospitalization    
for heart failure, mortality6,7), the rate of non-responders is significantly higher (up to           
40-46%) suggesting presence of certain degree of placebo response to device implantation. 
On the other hand, the later rate may be overestimated as the duration of the follow-up may be 
too short for some CRT recipients to reach the target improvement in the selected parameter. 
Despite that, however, as the rate of CRT non-responders represents a substantial 
proportion of CRT recipients, there is an effort to identify factors that can help to predict 
better the response to CRT. Until now, some parameters have been shown to be useful,         
but single, easily obtainable marker is still missing. 
PREDICTORS OF RESPONDERITY TO CRT
The findings of some studies indicated that the larger the baseline mechanical 
asynchrony, the more significant hemodynamic benefit during CRT could be 
expected91,139,140. In addition, certain association between mechanical dyssynchrony,           
QRS duration and baseline contractility was suggested91. First acute hemodynamic studies 
concluded that the QRS duration ≥150ms (especially in combination with baseline LV dP/dt 
max <600-700mmHg/s) is able to distinguish patients exhibiting acute improvement          
from those who do not improve most likely during both BVP and LVP87,89,116,134. However, 
extensive research in last years demonstrated that the usefulness of QRS duration                
and morphology as the only parameters for identification of significant mechanical 
asynchrony is limited141. There are two main reasons for that: 
1) QRS duration reflects the total ventricular activation time. Although some differences may 
exist between various conduction disturbances, generally, the type of bundle branch block    
and QRS width do not carry accurate information about the presence and the degree               
of mechanical inter- or intraventricular asynchrony28,141. 
2) Echocardiographic studies demonstrated that dyssynchronous LV contraction is present 
also in 33-58% of heart failure patients with narrow QRS complex (<120ms)28,141-144 and that 
CRT is able to improve mechanical ventricular synchrony also in these patients145-147. Such 
findings suggest that the measurement of mechanical, rather than electrical dyssynchrony is 
more important for estimating the effect of CRT99. 
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Therefore, various 
imaging techniques were 
advocated to define reliable 
parameters of mechanical 
dyssynchrony. Among them, 
echocardiography seems to 
be the most useful. Until 
now, many different markers 
of mechanical dyssynchrony 
were described using either 
standard 2D and Doppler 
echocardiography or tissue-Doppler-derived imaging (Table 2). However, usefulness of all 
these ECHO parameters in prediction of CRT responderity is still not completely known     
and has to be further evaluated in prospective multicenter trials148. 
Mechanical ventricular dyssynchrony seems to be the most crucial prerequisite          
for hemodynamic improvement during CRT. However, there are some other variables 
modifying the final outcome of CRT such as the underlying heart disease. Specifically, 
patients with ischemic etiology and the presence of scar are more likely to not 
respond136,149,150. Moreover, it seems that a greater basal LV dilatation and lower LV ejection 
fraction are more often associated with a lack of response to CRT121. Besides the selection     
of appropriate candidates of CRT, the final effect of this therapy seems to be modified           
by some periimplant variables like 1/ the type of pacing strategy (BVP, LVP), 2/ selection     
of the optimal pacing site(s) or 3/ optimization of atrioventricular or interventricular delay. 
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THE AIM OF THE WORK




THE AIM OF THE WORK
The aim of this PhD was, therefore: 
1/ to compare the effect of different pacing strategies that were proposed as alternatives of 
CRT (biventricular (BVP), single-site left-ventricular (LVP) and bifocal pacing of the right 
ventricle (BFP)) on the activation sequence, hemodynamic and clinical outcome of patients 
with advanced CHF, 
2/ to identify factors modifying the degree of CRT-related improvement.
Specifically, this PhD study addressed these issues:
1/ Description of electrical activation sequence during different pacing modes (BVP, 
LVP, BFP).
Until recently, there was only little known about the activation sequence of the heart               
in the presence of different conduction disturbances. In addition, most of these observations 
were based on the experimental models44,99,151. Introduction of new technologies, such as      
the electroanatomical mapping system, enables to study the activation pattern directly           
in the target population of patients with advanced CHF. Such studies contribute to our 
understanding of the pathophysiological and pacing-induced changes of electrical inter-       
and intraventricular dyssynchrony that are tightly related to the changes of the contraction 
pattern and hemodynamics. 
2/ Comparison of the acute effect of BVP and LVP during exercise
Studies reporting similar effect of LVP and BVP in patients with advanced CHF and manifest 
dyssynchrony reflect mostly hemodynamic status at rest. However, only limited data are still 
available on the effect of both pacing modalities during the exercise. In fact, such studies     
are highly important as the aim of CRT is not only to reduce symptoms at rest, but mainly     
to increase the exercise tolerance of CRT recipients. Therefore, we evaluated the impact        
of both pacing strategies on the acute changes of cardiac output (assessed noninvasively using 
stress echocardiography) during symptoms-limited exercise. 
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3/ Importance of RV pacing site optimization in CRT 
It seems that the crucial prerequisite for LV function enhancement during CRT                        
is preexcitation of the most delayed wall by LV pacing. Therefore, the optimal pacing site 
within the LV was predominantly studied in the past. Most studies reported the greatest 
improvement during pacing from the lateral/ posterolateral LV wall152-158. However, optimal 
pacing site may vary interindividually based on the type of conduction disturbance, scar 
location etc. It was shown that the correspondence of the site of late electromechanical 
activation and site of pacing provides the greatest benefit in terms of LV reverse remodeling, 
whereas no effect or worsening can be present when paced from remote sites158. 
Surprisingly, there are still only limited data about the importance of RV pacing site 
optimization in CRT. Therefore, we assessed the impact of RV pacing site on the long-term 
clinical outcome of CRT recipients in our third study. We hypothesized that 1/ the selection   
of suitable RV pacing site may, at least partially, affect the final effect of CRT and 2/ RV lead 
should be rather placed in region ensuring rapid ventricular activation resembling                 
the physiological activation pattern. We further presumed that RV midseptal (RVS) location 
could fulfill such criteria. 
4/ Impact of different atrio-ventricular and interventricular delay setting in BVP and 
LVP on acute changes of cardiac output.
The importance of atrioventricular and interventricular delay (AVD and VVD resp.) 
optimization emerges from the physiology of the cardiac cycle: 1/ Atrial contraction 
contributes to the stroke volume by approximately 20-40% in the heart with either normal      
or depressed systolic function159-161. Both atrioventricular (AV) block and/or presence            
of LBBB (despite normal electrical AV conduction)162,163 may cause prolongation                  
of mechanical AVD with shortening of the LV filling time due to fusion of the early passive 
filling phase with the atrial systole-dependent flow25,161,164. As the performance of the failing 
heart is dependent on an elevated preload, this summation may lead to a decrease of the stroke 
volume. 2/ In addition, appropriate AVD setting seems to reduce LV asynchrony (both intra-
and interventricular)44,93 due to the phenomenon of fusion. 3/ Finally, AVD and VVD 
optimization may contribute to the improved hemodynamics due to a reduction of mitral 
regurgitation165-167.
As the mechanical AVD may be longer than the corresponding electrical AVD            
in LBBB patients, we presumed 1/ that the shorter electrical AVD may be optimal                 
for a prolongation of the filling phase and maximal hemodynamic improvement in CRT 
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recipients as compared to the optimal AVD in conventional pacemakers. In addition, some 
studies in patients with preserved LV systolic function suggest that the spontaneous atrial 
activation during atrial-triggered ventricular pacing (atrial sense followed by ventricular 
pacing at a predetermined AV delay, S-AVD) is hemodynamically superior to AV sequential 
pacing (paced both atrium and ventricle with a predetermined AV delay, P-AVD)168. 
Therefore, we assessed 2/ if it is similar in CRT recipients. Finally, 3/ need of individual AVD 
optimization and 4/ effect of various degree of ventricular preexcitation (VVD) on the acute 
hemodynamic changes were assessed in the last study of this PhD.  
METHODS
Patients included in the studies fulfilled accepted criteria for CRT: advanced CHF   
with persistent symptoms despite optimized medical treatment (NYHA class III-IV),            
LV dysfunction (LV ejection fraction (LVEF) <30-35%, QRS duration >150ms (in most 
cases), LV dilatation (LV end-diastolic diameter (LVEDD) > 60mm). The study populations 
were of different size: twenty patients were enrolled in study 1, 28 patients in study 2,           
99 and 19 patients were included in study 3 and 4. Underlying heart disease was either 
coronary artery disease or idiopathic dilated cardiomyopathy or their combination. In few 
cases, coincidence of previsouly corrected valvular disease and ischemic cardiomyopathy   
was present (study 2 and 3). The mean age of enrolled patients was close to 60 years in all 
studies. Patients with CHF decompensation requiring catecholamine support, those             
with a recent history of myocardial infarction (<6 months) and/or angina pectoris of III-IV 
degree were excluded from all analyses. Except study 1, presence of atrial fibrillation          
was another exclusion criterium. On the other hand, patients with complete AV block (either 
spontaneous or ablation-induced) were included in studies 1, 2 and 4. Upgrade                    
from conventional pacemaker to CRT was performed in indicated patients based on the above 
mentioned indication criteria and QRS duration during right-ventricular pacing >200ms.       
All patients gave their informed consent. 
DEVICE IMPLANTATION
Device providing CRT therapy was implanted in the left or right subclavian region. 
All pacing leads were implanted transvenously via subclavian route. Leads with active 
fixation were used for pacing of the right ventricle and right atrium in most cases.
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Right-ventricular lead was inserted either into the apex (RVA) or midseptal region 
(RVS) of the right ventricle. In the later case, pacing lead was first introduced to the high     
RV outflow tract and then pulled down along the IVS. Suitable RVS site was identified using 
both simultaneously recorded intracardial signal from the tip of RV pacing lead and 
radiographic appearance in at least 3 different views.
Left-ventricular pacing lead was introduced into a suitable tributary of the coronary 
sinus and placed laterally or posterolaterally in most cases. Alternative LV pacing site         
was used in patients with no suitable vessel in this region or in those with repeated lead 
dislocations, high pacing threshold, pacing of the diaphragm or phrenic nerve. In such cases, 
LV lead was inserted predominantly more posteriorly or anterolaterally.
For selection of the optimal right- and left-ventricular pacing site, periprocedural 
recording of the intracardial signal from the tip of the appropriate lead was used. The site         
with intracardial signal recorded in the most terminal portion of the QRS complex               
was assigned as the target place for LV lead insertion. Vice versa, signal preceeding               
or coincide with the onset of QRS complex and/or displaying sharp signal of the conduction 
system determined region for RVS pacing (Figure 5). 
The third electrode was inserted in 
the right atrium, usually in its appendage. 
Biventricular pacing was set in all patients 
after the implantation. BVP configuration 
was also let in long-term follow-up in all 
patients with succesfull LV lead insertion. 
LVP was obtained by temporary 
reprogramming of the CRT device. 
In addition, total of 7 patients with bifocal RV pacing was included in the study 1. 
This pacing strategy was predominantly indicated in those patients with unsucessfull LV lead 
implantation. For BFP, two leads were introduced in the RV with one placed in the apex and 
second in the high outflow tract of the RV.
ELECTROANATOMICAL ACTIVATION MAPPING (CARTO) – STUDY 1
Four-milimeter tip mapping catheter was introduced via vena and arteria femoralis   
into the right and left ventricle. The LV catheter was introduced retrogradely through            
the aortic valve and boluses of heparin were administered during the mapping as a prevention 
of thromboembolic events. Detail electroanatomical activation mapping during BVP, LVP     
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or BFP was performed using CARTO system (Biosense Webster, Haifa, Israel). AVD was set 
at 120ms for sensed and 150ms for paced AVD. Four patients with no intraventricular 
conduction disturbance who underwent radiofrequency ablation of the accessory pathway 
served as a control group. There were no procedure-related complications.
All 3D isochronal activation maps were subsequently analyzed by one operator.       
The local activation time of each point was defined by the onset of the first high-frequency 
component of the bipolar signal. Analysis of the unipolar signal was additionally used             
if the amplitude of the bipolar signal was <0.5mV or in the presence of fragmented potentials. 
Low-voltage signals (<0.2mV) with uncapture were labelled as a scar.
The ventricular activation sequence was described with regard to direction and number 
of the activation wavefronts. Left ventricular activation time (LVAT) was defined                 
by the interval between the earliest and the latest endocardial activation. Interventricular 
delaly was described as the time-difference between the earliest activation in the RV and LV 
respectively (negative values marked preexcitation of the LV). The transseptal time                
was defined by the interval between the pacing stimulus and the earliest LV endocardial 
activation in the septal region. Fusion between spontaneous and pacing-induced activation 
was considered to be present, when additional LV endocardial breakthrough corresponding 
with the RV pacing site was observed and was not present during the spontaneous rhythm.
STRESS ECHOCARDIOGRAPHY AND NONIVASIVE MEASUREMENT OF 
THE CARDIAC OUTPUT – STUDIES 2 AND 4
Impact of BVP and LVP on the acute changes of the cardiac output during exercise 
was assessed by stress echocardiography in study 2. The test was performed in the supine 
position using bicycle ergometer (Ergoline-ergometrics 900, Marquette Electroics MN, USA). 
After resting for 10minutes, exercise with stepwise workload increase by 25watts every 
3minutes was applied. The test was performed in the mornings of 2 consecutive days           
and the patients were randomly allocated to either BVP or LVP with crossover                       
on the following day. 
At the end of the resting phase and at the end of each exercise level, blood pressure 
and heart rate were measured noninvasively. In addition, cardiac output was assessed        
using velocity time integral formula with the sampling volume placed in the LV outflow tract. 
A mean value of velocity time integral obtained by averaging of three consecutive cycles    
was used for calculation of the cardiac output (CO).
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Similar approach to the estimation of CO was also applied in study 4. This study      
was focused on the impact of different AVD and VVD on the cardiac output during              
the following pacing modes: 1/ BiV-LV – BVP with preexcitation of the LV by 4ms,            
2/ BiV-RV – BVP with preexcitation of the RV by 4ms, 3/ LVP. We tested a sequence          
of sensed and paced AVD (i.e. AVD during atrial-trigerred ventricular pacing                       
and atrioventricular sequential pacing, resp.) in all three pacing modes. Range of 80-160ms 
for sensed and 120-160ms for paced AVD was tested. Changes of CO induced by various 
degree of ventricular preexcitation (interventricular delay, VVD) were then assessed         
during BVP with an optimal AVD. Preexcitation of either RV or LV by 4-20ms was tested 
(Figure 1 in study 4).  
LONG-TERM FOLLOW-UP – STUDIES 1-4
Following variables were evaluated every 3 months after the CRT implantation: 
clinical outcome including current NYHA functional class and change in exercise tolerance, 
medication, ECG, spiroergometry and check of the device function, pacing thresholds, 
sensings and impedances of all implanted pacing leads. In addition, echocardiographic 
evaluation assessing LVEDD and LVEF was performed routinelly every 3 months.
STATISTICAL ANALYSIS
The main findings were expressed as a mean ± standard deviation. For comparison     
in the group or between different groups, paired or unpaired t-test was used,                       
when appropriate. P-value <0.05 was considered as significant. Correlation between variables 
was assessed using Pearson correlation coefficient, independent predictors were then 
identified using discriminant analysis. 
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RESULTS
1. ELECTRICAL ACTIVATION SEQUENCE DURING DIFFERENT PACING 
MODES 
(STUDY 1)
Using electroanatomical mapping, activation pattern of both ventricles during different 
pacing modes (BVP, LVP, single-site RV pacing, BFP) was analysed. It was clearly shown 
that the activation sequence of the heart can be interindividually highly variable,        
depending on 1/ the type of conduction disturbace, 2/ pacing mode and 3/ placement             
of the pacing lead(s). In addition, underlying heart disease, specifically the presence             
and location of scar, participated on this variability of activation pattern. The conduction 
defect localized on the ventricular level predominantly determined the ventricular activation 
pattern. Moreover, this study highlighted the contribution and impact of spontaneous 
activation via right bundle on the degree and pattern of ventricular resynchronization,            
so called phenomenon of fusion. Our results indicate that the presence of fusion                      
of spontaneous conduction with LVP-induced wavefront mimicks ventricular activation 
sequence observed during BVP. More importantly, this study described factors that modify 
the degree of this fusion. Present study further demonstrated that various pacing strategies 
alter the degree of both intra- and interventricular dyssynchrony. In addition, this was the first 
study describing activation sequence during BFP to our knowledge.
2. COMPARISON OF THE ACUTE EFFECT OF BIVENTRICULAR AND SINGLE-
SITE LEFT VENTRICULAR PACING DURING EXERCISE (STUDY 2)
In the second study, effect of BVP and LVP on the acute, exercise-induced changes    
of stroke volume was assessed. The results of our study implied that similar exercise level   
can be reached during both BVP and LVP in most cases with preserved AV conduction. Our 
results also indicated that LVP is equivalent to BVP in terms of augmentation of cardiac 
output. In fact, LVP was associated with slightly better results at rest and during low-level 
exercise as compared to BVP. However, cardiac output increase did not differ between LVP 
and BVP during higher exercise-levels. In addition, we observed superiority of one the modes 
in about 80% of all cases. Interestingly, superiority of LVP was seen predominantly              
in patients with DCM in our study. This might be related to a different expression of the inter-
and intraventricular dyssynchrony among patients with DCM and CAD.
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3. VENTRICULAR PACING SITE(S) (STUDY 3 & REVIEW) 
The aim of the third study of this PhD was to assess the importance of RV lead 
positioning in CRT recipients. The review summarizes current data about the hemodynamic 
consequences of alternative RV pacing sites that served as a rationale for study 3.
To our knowledge, our study was the first study assessing the impact of RV lead 
positioning on the long-term outcome of CRT. Its results confirmed our hypothesis that        
the selection of RV pacing site in CRT recipients affects the extent of LV reverse remodeling 
with more favourable results when paced from midseptal region. Less pronounced reverse 
remodeling was observed in patients with RV lead placed in the apical region. However, trend 
towards reduction of LVEDD was visible also among the later group, but after 2-3 times 
longer period than in the patients with midseptal pacing. This observation may suggest that 
CRT related reverse remodeling is also time-dependent. In addition, this study demonstrated 
that midseptal pacing is associated with a shortening of the total electrical activation             
(as expressed by the duration of QRS complex) during both single-site RV pacing and BVP. 
In accordance with other studies, however, we did not find relationship between the degree    
of reverse remodeling and either QRS duration or the extent of the QRS narrowing. 
4. IMPACT OF DIFFERENT ATRIOVENTRICULAR AND INTERVENTRICULAR 
DELAYS ON CARDIAC OUTPUT DURING CRT (STUDY 4)
Our last study demonstrated that the acute hemodynamic benefit of ventricular pacing 
is primarily dependent on the pacing mode, but using any pacing mode or site, the benefit       
is titrated by selected AVD. Our results shown nonsignificantly higher CO during the atrial-
trigered than during AV sequential CRT pacing. Optimal P-AVD was constantly longer      
than the optimal S-AVD during CRT and no significant correlation with spontaneous           
AV conduction was found. In addition, it was possible to identify an optimal S-AVD           
and P-AVD in most patients as the distribution of CO during different AVD setting              
was a bell-shaped curve with the maximum around 120ms for S-AVD and 140ms for P-AVD, 
respectively. However, CO changed only minimally in some patients and optimum value    
was often shifted to the right in these cases. This finding emphasized the necessity to optimize 
AVD individually as we have not identified any independent predictor of this AVD behavior.
Regarding VVD optimization, our findings suggest that the optimization of VVD     
may partially modify hemodynamics during CRT. LV preexcitation or simultaneous BVP   
was favorable in majority of our patients. Preexcitation of RV was constantly associated    
with worse hemodynamic performance.
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Cardiac resynchronization therapy (CRT) represents an accepted treatment modality   
in patients with advance chronic heart failure, acute and long-term benefit of which             
was confirmed in several clinical trials. Recently, reduced mortality and rate of hospitalization 
for heart failure were also demonstrated. However, response to CRT is interindividually 
highly variable with a substantial proportion of CRT recipients who do not respond to this 
therapy. 
Although the identification of suitable candidates is probably the most important 
factor in the reduction of the rate of non-responders, some other determinants, peri- and post-
implant, may substantially affect the final effect of CRT. The present PhD focused on some   
of these variables:
1/ First of them is a selection of the appropriate pacing mode. This PhD evaluated 
effect of 3 pacing modalities that have been proposed as alternatives of CRT – biventricular
pacing (BVP), single-site left-ventricular pacing (LVP) and right-ventricular bifocal pacing 
(BFP). It was clearly shown that the first two pacing strategies, BVP (i.e. simultaneous pacing 
of both ventricles) and LVP, cause comparable acute hemodynamic improvement at rest. 
Study No.2 of this PhD confirmed that the comparable effect of BVP and LVP is preserved 
also during the exercise. 
In addition, study No.1 described the character of ventricular activation during            
all 3 pacing strategies and explained the reasons for comparable hemodynamic benefit              
of BVP and LVP by restoration of more physiological activation sequence with merge           
of two activation wave fronts in the middle of the left ventricle. On the contrary, based          
on our experience from the long-term follow-up, BFP (simultaneous pacing                        
from the apex and outflow tract of the right ventricle) is only rarely associated                   
with the clinical improvement. Possible reasons for the inferiority of BFP as compared          
to BVP and/or LVP on the electrical level is the inability to correct the intraventricular 
asynchrony by BFP.
2/ Besides the selection of pacing mode, the pacing site is very important determinant 
affecting the final outcome of CRT. Optimal regions for insertion of the left-ventricular lead 
were studied by many investigators in the past. However, the issue of proper right-ventricular 
(RV) lead positioning in BVP was not addressed before. In fact, our study was the first one 
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that demonstrated additional benefit when using RV midseptal region as compared                 
to RV apex for long-term BVP (study No.3). More significant and earlier reverse remodeling 
of the ventricles was observed when paced from the midseptal region.
3/ Last, but not least, the final benefit of CRT is titrated, at least partially,                   
by the atrioventricular and interventricular delay programming (AVD and VVD) due             
to modification of the degree of inter- and/or intraventricular resynchronization. Study No.4 
of this PhD indicated that the cardiac output changes with selected AVD and VVD, with the 
optimum usually around 120ms and 140ms for sensed and paced AVD resp.                        
and preexcitation of the left ventricle in range 4-12ms for the VVD. Variable response           
to changed AVD and VVD setting in some patients, however, suggested the superiority             
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